


What is claimed is:

1. A combination comprising two anti-epileptics selected from the list consisting of barbiturates and derivatives thereof, benzodiazepines, carboxamides, hydantoins, succinimides, valproic acid and other fatty acid derivates, AMPA antagonists and other anti-epileptic drugs, in which the anti-epileptics are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
2. Combination according to claim 1 which is a combined preparation or a pharmaceutical composition.
3. Combination according to claim 1 or 2 comprising a carboxamide.
4. Combination according to any one of claims 1 to 3 comprising an AMPA antagonist.
5. Combination according to claim 1 or 2 wherein the two anti-epileptics are selected from carboxamides and an AMPA antagonist of formula I



wherein


R<sub>1</sub> is hydroxy or (C<sub>1-4</sub>)alkyl,

R<sub>2</sub> is hydrogen or (C<sub>1-4</sub>)alkyl,

R<sub>3</sub> is hydrogen, (C<sub>1-4</sub>) alkyl, fluorine, chlorine, bromine, trifluoromethyl, cyano or nitro, and

X is (C<sub>1-6</sub>)alkylene, (C<sub>1-6</sub>)alkylidene, (C<sub>1-6</sub>)alkylene(C<sub>3-6</sub>cycloalkylene or (C<sub>1-6</sub>)alkylene-(C<sub>3-6</sub>cycloalkylidene.

6. Combination according to claim 5 wherein the carboxamide is selected from carbamazepine, oxcarbazepine, 10-hydroxy-10,11-dihydrocarbamazepine and the compounds of formula II



wherein  $R_1'$  represents acetoxy.

7. Combination according to claim 5 or 6, wherein in the formula I  $R_1$  is hydroxy,  $R_2$  is hydrogen,  $R_3$  is nitro and  $X$  is methylene.

8. Combination according to any one of claims 1 to 7 for simultaneous, separate or sequential use in the treatment of epilepsy.

9. Method of treating a warm-blooded animal having epilepsy comprising administering to the animal a combination according to any one of claims 1 to 7 in a quantity which is jointly therapeutically effective against epilepsy and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

10. A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against epilepsy, of a pharmaceutical combination according to any one of claims 1 to 7 and at least one pharmaceutically acceptable carrier.

11. Use of a combination according to any one of claims 1 to 7 for the preparation of a medicament for the treatment of epilepsy.

12. Use according to claim 7 or 11 wherein the epilepsy is refractory to monotherapy.

13. A commercial package comprising a combination according to any one of claim 1 to 7 together with instructions for simultaneous, separate or sequential use thereof in the treatment of epilepsy.